Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury

Inclusion Criteria: 1. Male or female aged 18-75 years; 2. Patients with malignant tumor accord with chemotherapy indication, candidate to a chemotherapy treatment, disease is not restricted; 3. Accorded with the following chemotherapy plan: included cis-platinum, ≥60mg/m2/course; included oxaliplatin, ≥85mg/m2/course; included cyclophosphamide, ≥600mg/m2/course; included gemcitabine, ≥60mg/m2/course; 4. ECOG≤2; 5. Estimates survival time≥3 months; 6. TBIL≤1.0×ULN, ALT、AST≤1.0×ULN; blood examination, uronoscopy, stool examination, renal function tests and electrocardiogram are normal; 7. Patients have been apart from the previous chemotherapy to finish above 2 weeks (including 2 weeks). Exclusion Criteria: 1. Patients with partial liver radiotherapy; 2. Hepatitis B or C virus replication in the state, the patient will need antiviral therapy; 3. Patients have serious heart diseases, liver kidney diseases, or metabolism function disorder; 4. Patients combined with cellular immune therapy; 5. Within 2 weeks of application or currently possible applications of drugs(polyene phosphatidylcholine, reduced glutathione, tiopronin and other hepatoprotective and choleretic drugs), interference with the study; 6. Pregnancy, or patients during breast feeding; 7. Patients have known hypersensitivity to Glycyrrhizin; 8. Patients are participating, or have participated in other Clinical studies of new drugs within 4 weeks.